Business Context and Reporting Period
This Form 8-K Current Report is filed by Acurx Pharmaceuticals, Inc. (ACXP), a Delaware corporation and emerging growth company, for the event date of July 31, 2025. The filing addresses a material modification to the rights of security holders regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a notice of a corporate action.
Material Changes
The primary material change reported is a 1-for-20 reverse stock split of the Company's common stock. Key details include:
- Effective Time: 4:01 p.m. Eastern Time on August 4, 2025.
- Trading Resumption: Post-split trading is expected to begin on The Nasdaq Capital Market on August 5, 2025.
- Conversion Ratio: Every 20 shares of issued and outstanding Common Stock will be converted into 1 share.
- Par Value: No change to the par value per share ($0.001).
- Adjustments: Proportionate adjustments will be made to exercise prices and share counts for outstanding stock options, warrants, convertible securities, and the stock incentive plan.
- Fractional Shares: Shareholders entitled to fractional shares will receive a cash payment based on the closing sales price on the trading day immediately prior to the Effective Time.
- Symbol and CUSIP: The stock will continue to trade under the symbol "ACXP" with a new CUSIP number of 00510M 203.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary is qualified by the full text of the Certificate of Amendment. The reverse stock split is intended to adjust the share count and price per share, typically to meet or maintain listing standards, though the filing does not explicitly state the strategic rationale beyond the execution of the amendment.
Investor Verification Checklist
- Verify the exact number of shares held prior to the split to calculate the post-split share count (dividing by 20).
- Confirm the treatment of fractional shares and the specific closing price used for cash-in-lieu calculations.
- Check the updated CUSIP number (00510M 203) for trading and settlement purposes starting August 5, 2025.
- Review the impact on outstanding options and warrants, specifically the adjusted exercise prices and share quantities.
- Monitor the stock price performance on The Nasdaq Capital Market immediately following the effective time to assess market reaction.